Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Urology
Volume 2015, Article ID 198381, 4 pages
http://dx.doi.org/10.1155/2015/198381
Case Report

Acute Respiratory Distress Syndrome after Treatment of Metastatic Prostate Cancer with Taxotere: A Case Report and Literature Review

Division of Hematology-Oncology, Department of Medicine, Joan C. Edwards School of Medicine, Marshall University, Edward Comprehensive Care Center, Huntington, WV 25701, USA

Received 23 May 2015; Revised 28 July 2015; Accepted 29 July 2015

Academic Editor: Fumitaka Koga

Copyright © 2015 Ali Raufi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. D. A. Loblaw, K. S. Virgo, R. Nam et al., “Initial hormonal management of Androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American society of clinical oncology practice guideline,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1596–1605, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. I. F. Tannock, R. de Wit, W. R. Berry et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1502–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. D. P. Petrylak, C. M. Tangen, M. H. A. Hussain et al., “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1513–1520, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. C. N. Sternberg, H. Dumez, H. Van Poppel et al., “Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer,” Annals of Oncology, vol. 20, no. 7, pp. 1264–1269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. W. K. Kelly, S. Halabi, M. Carducci et al., “Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401,” Journal of Clinical Oncology, vol. 30, no. 13, pp. 1534–1540, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. D. I. Quinn, C. M. Tangen, M. Hussain et al., “SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC),” Journal of Clinical Oncology, vol. 30, supplement 15, article 4511, 2012. View at Google Scholar
  8. C. Sweeney, Y.-H. Chen, M. A. Carducci et al., “Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial,” Journal of Clinical Oncology, vol. 32, supplement 5, abstract LBA2, 2014. View at Google Scholar
  9. M. J. Edelman, “Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer,” Clinical Lung Cancer, vol. 10, supplement 1, pp. S30–S34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. K. L. Hennenfent and R. Govindan, “Novel formulations of taxanes: a review. Old wine in a new bottle?” Annals of Oncology, vol. 17, no. 5, pp. 735–749, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. W. J. Gradishar, S. Tjulandin, N. Davidson et al., “Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7794–7803, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Harries, C. Moss, T. Perren et al., “A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer,” British Journal of Cancer, vol. 91, no. 4, pp. 627–632, 2004. View at Google Scholar · View at Scopus
  13. M. L. Hensley, J. A. Blessing, R. Mannel, and P. G. Rose, “Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial,” Gynecologic Oncology, vol. 109, no. 3, pp. 329–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Gligorov and J. P. Lotz, “Preclinical pharmacology of the taxanes: implications of the differences,” The Oncologist, vol. 9, supplement 2, pp. 3–8, 2004. View at Google Scholar
  15. E. C. Rosenow III and A. H. Limper, “Drug-induced pulmonary disease,” Seminars in Respiratory Infections, vol. 10, no. 2, pp. 86–95, 1995. View at Google Scholar · View at Scopus
  16. L. S. Snyder and M. I. Hertz, “Cytotoxic drug-induced lung injury,” Seminars in Respiratory Infections, vol. 3, no. 3, pp. 217–228, 1988. View at Google Scholar · View at Scopus
  17. U. Jehn, N. Göldel, R. Rienmüller, and W. Wilmanns, “Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia,” Medical Oncology and Tumor Pharmacotherapy, vol. 5, no. 1, pp. 41–47, 1988. View at Google Scholar · View at Scopus
  18. J. H. Ryu, “Chemotherapy-induced pulmonary toxicity in lung cancer patients,” Journal of Thoracic Oncology, vol. 5, no. 9, pp. 1313–1314, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Vahid and P. E. Marik, “Pulmonary complications of novel antineoplastic agents for solid tumors,” Chest, vol. 133, no. 2, pp. 528–538, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Joerger, A. Gunz, R. Speich, and B. C. Pestalozzi, “Gemcitabine-related pulmonary toxicity,” Swiss Medical Weekly, vol. 132, no. 1-2, pp. 17–20, 2002. View at Google Scholar · View at Scopus
  21. J. Watkins, J. H. Slade, A. Phan, C. Eng, A. Weissferdt, and M. J. Overman, “Fatal diffuse alveolar damage associated with oxaliplatin administration,” Clinical Colorectal Cancer, vol. 10, no. 3, pp. 198–202, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Lafaras, E. Mandala, E. Verrou et al., “Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study,” Annals of Oncology, vol. 19, no. 10, pp. 1765–1769, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Schrijvers, J. Wanders, L. Dirix et al., “Coping with toxicities of docetaxel (Taxotere),” Annals of Oncology, vol. 4, pp. 610–611, 1993. View at Google Scholar
  24. M. E. Trudeau, E. A. Eisenhauer, B. P. Higgins et al., “Docetaxel in patients with metastatic breast cancer a phase ii study of the national cancer institute of canada-clinical trials group,” Journal of Clinical Oncology, vol. 14, no. 2, pp. 422–428, 1996. View at Google Scholar · View at Scopus
  25. M. J. Piccart, J. Klijn, R. Paridaens et al., “Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the european organization for research and treatment of cancer investigational drug branch for breast cancer,” Journal of Clinical Oncology, vol. 15, no. 9, pp. 3149–3155, 1997. View at Google Scholar · View at Scopus
  26. E. Briasoulis and N. Pavlidis, “Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy,” The Oncologist, vol. 6, no. 2, pp. 153–161, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. M. L. Dunsford, G. M. Mead, A. C. Bateman, T. Cook, and K. Tung, “Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma,” Annals of Oncology, vol. 10, no. 8, pp. 943–947, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Bonnichon, L. Vedrine, M. Aletti et al., “Favorable outcome of gemcitabine-induced acute respiratory distress syndrome,” Revue de Pneumologie Clinique, vol. 63, no. 6, pp. 379–383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Gamelin, S. Jeanson, F. Chenue et al., “Acute respiratory distress syndrome after injection of leuprorelin,” Therapie, vol. 50, no. 6, pp. 587–588, 1995. View at Google Scholar
  30. P. Zappasodi, R. Dore, C. Castagnola et al., “Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma,” Journal of Clinical Oncology, vol. 25, no. 22, pp. 3380–3381, 2007. View at Publisher · View at Google Scholar · View at Scopus